ClinicalTrials.gg
CompletedNCT00180050Updated Mar 30, 2010

Budesonide Treatment for Lymphocytic Colitis

A Phase 3 interventional study of Budesonide in Microscopic Colitis, sponsored by Technische Universität Dresden. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-03-30.

Sponsored by Technische Universität Dresden · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis

Read the detailed description

The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis

02

Conditions studied

  • Microscopic Colitis

Browse trials for

Keywords

  • lymphocytic colitis
  • microscopic colitis
  • budesonide
03

In context

Colitis, Microscopic

23 studies on the registry are indexed under Colitis, Microscopic; 6 are open to participants now.

This study's planned enrollment of 40 is below the median of 47 across 14 interventional studies indexed under Colitis, Microscopic.

Browse Colitis, Microscopic studies →

Lead sponsor

Technische Universität Dresden is the lead sponsor of 247 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • lymphocytic colitis
  • diarrhea
  • effective
  • written

Exclusion criteria

Exclusion Criteria:

  • other forms if IBD
  • celiac disease
  • infectious colitis
  • history of colonic surgery
  • use of budesonide, 5-ASA, within th previous 4 weeks
  • pregnancy, lactation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
40 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients in clinical remission after 6 weeks

Secondary outcomes

  1. safety

  2. quality of life

  3. histological improvement

07

Study locations

1 site
  • Medical Department I, Technical University Hospital
    Dresden, 01307, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of Aug 2006 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 16, 2005
Start
Jan 2002
Primary completionActual
Aug 2006
CompletionActual
Aug 2007
Last update
Mar 30, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00180050
First posted
Sep 16, 2005
Start date
Jan 2002
Primary completion
Aug 2006
Completion
Aug 2007
Last update
Mar 30, 2010

Study contacts

Stephan Miehlke, Prof.
principal investigator · Medical Department I, Technical University Hospital, Dresden, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion